Lupin Enters $184 Mn US Market with Launch of Prucalopride Tablets

’s USFDA-approved launch of Prucalopride tablets (1 mg and 2 mg) strengthens its position in the US specialty generics space. Targeting chronic idiopathic constipation (CIC) in adults, the product enters a niche segment with an annual market size of $184 million. Manufactured at Lupin’s Goa facility, this launch adds to its US pipeline and reflects the company’s ongoing push to scale high-value products with regulatory clarity and cost competitiveness. While the entry is timely and strategic, execution and pricing dynamics in the competitive US market will be key to unlocking its full revenue potential. Follow me for more such updates, Thank You! Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.